AstraZeneca PLC (NASDAQ:AZN) Receives Average Rating of “Hold” from Brokerages

AstraZeneca PLC (NASDAQ:AZNGet Free Report) has received a consensus rating of “Hold” from the six research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $80.00.

Several brokerages have recently issued reports on AZN. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Jefferies Financial Group lowered AstraZeneca from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Morgan Stanley began coverage on AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating for the company. Finally, HSBC began coverage on AstraZeneca in a report on Monday, December 18th. They set a “buy” rating for the company.

Get Our Latest Stock Report on AZN

AstraZeneca Trading Up 0.5 %

Shares of NASDAQ AZN opened at $66.50 on Friday. AstraZeneca has a one year low of $60.47 and a one year high of $76.56. The firm has a market capitalization of $206.18 billion, a PE ratio of 34.64, a PEG ratio of 1.19 and a beta of 0.49. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.57. The business has a 50-day moving average price of $66.11 and a two-hundred day moving average price of $65.96.

AstraZeneca (NASDAQ:AZNGet Free Report) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. The business had revenue of $12.02 billion for the quarter, compared to analyst estimates of $12.07 billion. During the same quarter in the previous year, the business posted $0.69 earnings per share. The company’s revenue was up 7.3% compared to the same quarter last year. As a group, analysts predict that AstraZeneca will post 4.07 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which will be paid on Monday, March 25th. Investors of record on Friday, February 23rd will be paid a $0.965 dividend. This represents a dividend yield of 2.3%. This is an increase from AstraZeneca’s previous Semi-Annual dividend of $0.47. The ex-dividend date is Thursday, February 22nd. AstraZeneca’s dividend payout ratio (DPR) is presently 100.52%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. ICA Group Wealth Management LLC bought a new position in shares of AstraZeneca in the 4th quarter valued at approximately $42,000. SageView Advisory Group LLC bought a new position in shares of AstraZeneca in the 4th quarter valued at approximately $436,000. Willner & Heller LLC bought a new position in shares of AstraZeneca in the 4th quarter valued at approximately $314,000. Fisher Asset Management LLC increased its position in AstraZeneca by 2.2% in the 4th quarter. Fisher Asset Management LLC now owns 9,376,193 shares of the company’s stock worth $631,487,000 after buying an additional 205,185 shares during the period. Finally, American International Group Inc. increased its position in AstraZeneca by 2.0% in the 4th quarter. American International Group Inc. now owns 40,464 shares of the company’s stock worth $2,725,000 after buying an additional 775 shares during the period. 15.68% of the stock is owned by institutional investors.

AstraZeneca Company Profile

(Get Free Report

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Read More

Analyst Recommendations for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.